PRESENTER
Whitney Hauser, OD, FAAO
Director, Peer Education for US Eye Care
Novartis Pharmaceuticals Corporation
Complimentary Webinar
Connecting the Dots:
Xiidra (lifitegrast ophthalmic solution) 5% in Action
at New Technologies & Treatments in Eye Care 2020
Saturday, October 17th | Friday, November 13th
Educate health care professionals on the management of chronic dry eye disease and the role of Xiidra for the treatment of the signs and symptoms of dry eye disease.
Whitney Hauser, OD, FAAO
Director, Peer Education for US Eye Care
Novartis Pharmaceuticals Corporation
Dr. Whitney Hauser, has joined Novartis as the Director, Peer Education for US Eye Care. As part of the Novartis commitment to professional education, Dr. Hauser will help shape our education and engagement strategy with the Eye Care community. Dr Hauser is an employee of and paid by Novartis.
Dr. Hauser brings deep experience as both a clinician and educator to the topic of dry eye. She graduated from the Southern College of Optometry, where she later served as Associate Professor until 2019. Dr. Hauser has authored many articles focusing on the management and treatment of ocular surface disease. She is also one of the founding members of the Intrepid Eye Society, a board member of the Ocular Surface Society of Optometry (OSSO) and in 2014 founded Dry Eye Coach, where she consulted other clinicians treating Dry Eye Disease. In 2018, Dr. Hauser was named a Theia Award winner and named among the Most Influential Women in Optical by Vision Monday.
Prior to joining Novartis, Dr. Hauser served as the Director of Clinical Affairs for Keplr Vision, where she specialized in the implementation of medical standards and services to the group’s network of 120+ practices across the United States. She also previously served as a Clinical Director and Research Coordinator for Toyos Eye Clinic, an ophthalmology referral center. Dr. Hauser practiced clinical care at The Eye Specialty Group in Memphis, Tennessee with a focus on ocular surface disease and surgical management.
Indication
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).
Important Safety Information
Click here for Full Prescribing Information
XIIDRA, the XIIDRA logo and ii are registered trademarks of Novartis AG.
10/20 XIA-1396428
Sponsored by:
Brought to you by: Medscape
Medscape Privacy Policy